# David Cunningham

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-cunningham/

## Facts

| Field | Value |
| --- | --- |
| Citations | 132,293 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 153 |
| i10-index | 928 |
| Last Known Institution | Royal Marsden NHS Foundation Trust |
| OpenAlex ID | https://openalex.org/A5056345420 |
| ORCID iD | https://orcid.org/0000-0001-5158-1069 |
| Works | 2,042 |

## Researcher papers

- [Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-patients-with/)
- [Colorectal cancer](https://scholariq.org/papers/colorectal-cancer-3/)
- [Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer](https://scholariq.org/papers/final-results-from-prime-randomized-phase-iii-study-of-panitumumab-with-folfox4/)
- [Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial](https://scholariq.org/papers/epcoritamab-a-novel-subcutaneous-cd3xcd20-bispecific-t-cell-engaging-antibody-in/)
- [First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials](https://scholariq.org/papers/first-line-selective-internal-radiotherapy-plus-chemotherapy-versus-chemotherapy/)
- [A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF)](https://scholariq.org/papers/a-phase-ii-study-in-advanced-gastro-esophageal-cancer-using-epirubicin-and/)
- [Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial](https://scholariq.org/papers/prognostic-value-of-end-of-induction-pet-response-after-first-line/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

## Researcher university

- [Royal Marsden NHS Foundation Trust](https://scholariq.org/institutions/royal-marsden-nhs-foundation-trust/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.